India has rapidly positioned itself as the world’s leading hub for life sciences Global Capability Centers (GCCs). According to EY India’s latest report, “Reimagining Life Sciences Global Capability Centers (GCCs),” 23 of the world’s top 50 life sciences companies have established their GCCs in India—most within the past five years. This surge underscores India’s growing role in pharmaceutical research, digital innovation, and end-to-end value creation.
From Cost Centers to Innovation Engines
Once seen as cost-efficient back offices, life sciences GCCs in India have transformed into strategic innovation powerhouses. No longer limited to support functions, these centers now lead critical global mandates such as:
*Drug discovery and development
*Digital therapeutics
*Real-world evidence (RWE) analytics
By leveraging artificial intelligence, GCCs are accelerating drug pipelines and driving patient-centric innovation at scale.
Delivering End-to-End Value Across the Life Sciences Chain
Modern GCCs in India now manage integrated operations across the life sciences value chain, including:
*Core functions: clinical trials, pharmacovigilance, regulatory affairs, biostatistics
*Enabling functions: finance, HR, IT, and data analytics
The expansion has delivered measurable business outcomes, making these centers indispensable to global operations.
EY’s analysis shows sharp penetration across both enabling and core functions in the past five years:
*Enabling functions: 70% of finance, 75% of HR, 62% of supply chain, and 67% of IT functions are managed in India.
*Core functions: 45% penetration in drug discovery and development, 60% in regulatory affairs, 54% in medical affairs, and 50% in commercial operations.
This shift signifies India’s transition from a cost hub to a strategic innovation center powering global pharma and healthcare.
Expert View: India’s Strategic Evolution
Arindam Sen, Partner and GCC Sector Lead – Technology, Media and Entertainment and Telecommunications, EY India, said, “India has rapidly evolved from a support base to the very center of innovation for global pharma and healthcare. In just five years, GCC penetration in enabling functions like finance, HR, supply chain, and IT has crossed 60%. But what truly stands out is the deepening role in core functions—drug discovery, regulatory affairs, medical, and commercial operations. This isn’t about cost arbitrage anymore; it’s about India becoming indispensable to the global R&D pipeline.”
Why India Leads the GCC Revolution
Policy Support: Central and state governments recognize GCCs as engines of digital exports and job creation, offering incentives such as CAPEX subsidies, rental reimbursements, skilling programs, and land rebates. States like Karnataka, Telangana, Uttar Pradesh, and Madhya Pradesh are leading the charge.
Talent Advantage: With 2.7 million life sciences professionals, an annual pipeline of 2 million STEM graduates, and 110,000 medical graduates, India offers unmatched access to scientific, medical, and digital expertise.
Ecosystem Maturity: India boasts a thriving innovation ecosystem—global-quality CROs, top academic institutions, 100+ unicorns, and a dynamic startup culture, all fueling GCC-driven R&D.
Infrastructure Edge: The country provides Grade-A commercial spaces across metros and emerging Tier II/III cities, enabling scalable and cost-efficient operations.
Future Outlook: From Support Arm to Strategic Twin
The EY report highlights that leading life sciences GCCs are evolving into “twins” of global headquarters—co-owning innovation and accelerating business outcomes. Their journey ahead will be shaped by three imperatives:
*Building Future Capabilities: Driving transformation, resilience, and ecosystem collaboration.
*Evolving Operating Models: Moving from transactional delivery to outcome-based partnerships.
*Strengthening Talent: Developing agile, multi-disciplinary teams and upskilling in generative AI, bioinformatics, and digital health.
As per EY press release, as global pharma companies embed knowledge-intensive work in India, the country is no longer just a cost hub—it is the strategic core of life sciences innovation, compliance, and growth.
